Table 8.
Number of Samples Displaying (intermediate) Resistance to Different Drug Classes, According to ANRS, HIVDB, REGA, and Geno2Pheno.
| Data set | According to | ANRS | HIVDB | REGA | |||
|---|---|---|---|---|---|---|---|
| PI | RTI | PI | RTI | PI | RTI | ||
| Clinical | Exatype FASTA file | 82/126 (65%) | 51/126 (41%) | 33/126 (26%) | 42/126 (33%) | 34/126 (27%) | 41/126 (33%) |
| RECall FASTA file | 81/126 (64%) | 52/126 (41%) | 33/126 (26%) | 42/126 (33%) | 34/126 (27%) | 43/126 (34%) | |
| WHO Dry panel | Reference | 18/40 (45%) | 20/40 (50%) | 18/40 (45%) | 20/40 (50%) | 17/40 (43%) | 20/40 (50%) |
For the HIV-1 RNA remnant dataset, we included only the sequences that passed for both RECall, and Exatype editing. In contrast, we included resistance information of all reference sequences for the WHO dry panel dataset. FPR, false-positive rate; RTI, reverse transcriptase inhibitor; PI, protease inhibitor; genotypic drug resistance interpretation systems: ANRS version 27, HIVDB version 8.9-1 for the clinical dataset and HIVDB version 8.9-1 for the EQA dataset, and REGA version 8.0.2, G2P Geno2Pheno.